Updating targets for natural killer/T-cell lymphoma immunotherapy

Area of Science:

• Oncology
• Immunology
• Hematology

Background:

• Natural killer/T-cell lymphoma (NKTCL) is an aggressive non-Hodgkin lymphoma subtype with limited treatment options.
• Current therapies like chemotherapy, radiotherapy, and stem cell transplantation have significant drawbacks, including drug resistance, relapse, and limited efficacy.
• Immunotherapy has emerged as a promising area of research for NKTCL due to its potential for better clinical outcomes.

Purpose of the Study:

• To review and outline known immunotherapy targets for the treatment of NKTCL.
• To highlight the clinical activity of various immunotherapy agents in NKTCL.
• To discuss the potential of novel therapeutic strategies in NKTCL management.

Main Methods:

• Review of existing literature on immunotherapy in NKTCL.
• Analysis of clinical data for targeted antibodies (daratumumab, brentuximab vedotin), checkpoint inhibitors, and anti-CCR4 monoclonal antibodies (mAbs).
• Exploration of the role of IL10 and cellular immunotherapy (engineered cytotoxic T lymphocytes) in NKTCL treatment.

Main Results:

• Targeted antibodies like daratumumab and brentuximab vedotin show clinical activity in NKTCL.
• Checkpoint inhibitors are effective due to high programmed death-ligand 1 expression in NKTCL.
• Anti-CCR4 mAbs and cellular immunotherapy demonstrate promising results, including sustained remission.

Conclusions:

• Immunotherapy represents a significant advancement in NKTCL treatment, offering alternatives to conventional therapies.
• Targeted antibodies, checkpoint inhibitors, and cellular immunotherapy are key areas of development for NKTCL.
• Further research into novel targets like IL10 and optimization of cellular immunotherapy holds potential for improved NKTCL patient outcomes.